Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Holdings Increased by Zeno Equity Partners LLP

Zeno Equity Partners LLP boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,740 shares of the company’s stock after buying an additional 12,121 shares during the quarter. Medpace accounts for approximately 6.1% of Zeno Equity Partners LLP’s investment portfolio, making the stock its 9th largest position. Zeno Equity Partners LLP’s holdings in Medpace were worth $20,180,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Proficio Capital Partners LLC grew its position in shares of Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock worth $80,575,000 after buying an additional 241,827 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Medpace during the 4th quarter valued at about $78,144,000. Iron Triangle Partners LP purchased a new position in shares of Medpace in the 3rd quarter valued at approximately $64,371,000. GW&K Investment Management LLC increased its position in shares of Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after acquiring an additional 133,379 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.0 %

MEDP stock opened at $322.93 on Wednesday. The business has a 50 day simple moving average of $339.49 and a 200-day simple moving average of $340.34. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The company has a market capitalization of $9.84 billion, a P/E ratio of 25.57, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.